A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis
Year: 2013
Type: article
Study design: Observational Study
Abstract: OBJECTIVES: Despite significant medical advances, infective endocarditis (IE) remains an infection associated with high morbidity and mortality. The objective was to assess the safety and efficacy of high-dose daptomycin, defined as ≥ 8 mg/kg/day, in patients with confirmed or suspected staphylococcal and/or enterococcal IE. METHODS: This was a multicentre, retrospective observational study (2005-11). Adult patients, not undergoing haemodialysis, with blood cultures positive for staphylococci or enterococci and a definitive or possible diagnosis of IE, who received daptomycin ≥ 8 mg/kg/day (based on total body weight) for ≥ 72 h were included. RESULTS: Seventy patients met the inclusion criteria and comprised 33 (47.1%) with right-sided IE (RIE), 35 (50%) with left-sided IE (LIE) and 2 with both RIE and LIE. Several patients had concomitant sites of infection, with bone/joint infection being most prevalent (12.9%). Sixty-five patients received daptomycin as salvage therapy. Pathogens were isolated from 64 patients, with methicillin-resistant Staphylococcus aureus as the most common organism (84.4%), followed by vancomycin-resistant Enterococcus faecium (7.8%). The median (IQR) daptomycin dose was 9.8 mg/kg/day (8.2-10.0 mg/kg/day), and was similar in RIE and LIE patients (9.8 and 9.3 mg/kg/day, respectively). A total of 24 (34.3%) received combination therapy. For those patients with pathogens isolated (n = 64), the organism was eradicated in 57 (89.1%) patients. Among 64 clinically evaluable patients, 55 (85.9%) achieved clinical success. No patients required discontinuation of high-dose daptomycin due to creatine phosphokinase elevations. CONCLUSIONS: Patients with both RIE and LIE had successful outcomes with high-dose daptomycin therapy. Additional clinical trials evaluating high daptomycin dosages in patients with IE are warranted.
DOI: 10.1093/jac/dkt294
Authors: R. Kullar, A. M. Casapao, S. L. Davis, D. P. Levine, J. J. Zhao, C. W. Crank, J. Segreti, G. Sakoulas, S. E. Cosgrove, M. J. Rybak
Institutions: Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Henry Ford Health, Henry Ford Hospital, Detroit Medical Center, Harper University Hospital, Rush University Medical Center, Rush University, Sharp Memorial Hospital, University of California San Diego, Johns Hopkins University, Johns Hopkins Medicine
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Keywords: daptomycin, high-dose daptomycin, infective endocarditis, staphylococcal endocarditis, enterococcal endocarditis, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, right-sided endocarditis, left-sided endocarditis, salvage therapy, combination therapy, treatment efficacy, drug safety, creatine kinase elevation
Open Access status: green
Funder: U.S. Public Health Service
Award: G4262754010
OpenAlex ID: W2096479937
